Clinical Trials Logo

Cancer Nos clinical trials

View clinical trials related to Cancer Nos.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03052868 Completed - Cancer Nos Clinical Trials

Analysis of Neurocognitive Elements of Attention After Chemotherapy

Start date: July 2011
Phase: N/A
Study type: Interventional

Data for this study will be obtained from the University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center. Participants will be recruited through Simmons Cancer Center. One hundred female breast cancer patients who have completed adjuvant chemotherapy will be enrolled. In order to reach this number, it is estimated that up to 125 eligible participants will need to be recruited. The study will last approximately two years. Participants will undergo one cognitive testing session, and each subject's total participation time will last no more than two hours.

NCT ID: NCT01750580 Completed - CANCER, NOS Clinical Trials

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Start date: December 2012
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with ipilimumab in subjects with select advanced (metastatic and/or unresectable) solid tumors.

NCT ID: NCT01714739 Completed - CANCER,NOS Clinical Trials

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Start date: October 7, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination. In addition, to assess the combinations of lirilumab and nivolumab or lirilumab and nivolumab plus ipilimumab (BMS-734016) in subjects with advanced (metastatic and/or unresectable) refractory solid tumors.